Cargando…
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006453/ https://www.ncbi.nlm.nih.gov/pubmed/32076595 http://dx.doi.org/10.3389/fonc.2020.00001 |
_version_ | 1783495146901340160 |
---|---|
author | Oliva, Stefania D'Agostino, Mattia Boccadoro, Mario Larocca, Alessandra |
author_facet | Oliva, Stefania D'Agostino, Mattia Boccadoro, Mario Larocca, Alessandra |
author_sort | Oliva, Stefania |
collection | PubMed |
description | In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to the induction of the deepest possible response. As a result of these advances, a great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sensitivity techniques to detect minimal residual disease (MRD). In 2016, the International Myeloma Working Group (IMWG) updated MM response categories defining MRD-negative responses both in the bone marrow (assessed by next-generation flow cytometry or next-generation sequencing) and outside the bone marrow. MRD is an important factor independently predicting prognosis during MM treatment. Moreover, using novel combination therapies, MRD-negative status can be achieved in a fairly high percentage of patients. However, many questions regarding the clinical use of MRD status remain unanswered. MRD monitoring can guide treatment intensity, although well-designed clinical trials are needed to demonstrate this potential. This mini-review will focus on currently available techniques and data on MRD testing and their potential future applications. |
format | Online Article Text |
id | pubmed-7006453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70064532020-02-19 Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma Oliva, Stefania D'Agostino, Mattia Boccadoro, Mario Larocca, Alessandra Front Oncol Oncology In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to the induction of the deepest possible response. As a result of these advances, a great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sensitivity techniques to detect minimal residual disease (MRD). In 2016, the International Myeloma Working Group (IMWG) updated MM response categories defining MRD-negative responses both in the bone marrow (assessed by next-generation flow cytometry or next-generation sequencing) and outside the bone marrow. MRD is an important factor independently predicting prognosis during MM treatment. Moreover, using novel combination therapies, MRD-negative status can be achieved in a fairly high percentage of patients. However, many questions regarding the clinical use of MRD status remain unanswered. MRD monitoring can guide treatment intensity, although well-designed clinical trials are needed to demonstrate this potential. This mini-review will focus on currently available techniques and data on MRD testing and their potential future applications. Frontiers Media S.A. 2020-01-31 /pmc/articles/PMC7006453/ /pubmed/32076595 http://dx.doi.org/10.3389/fonc.2020.00001 Text en Copyright © 2020 Oliva, D'Agostino, Boccadoro and Larocca. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Oliva, Stefania D'Agostino, Mattia Boccadoro, Mario Larocca, Alessandra Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma |
title | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma |
title_full | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma |
title_fullStr | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma |
title_full_unstemmed | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma |
title_short | Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma |
title_sort | clinical applications and future directions of minimal residual disease testing in multiple myeloma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006453/ https://www.ncbi.nlm.nih.gov/pubmed/32076595 http://dx.doi.org/10.3389/fonc.2020.00001 |
work_keys_str_mv | AT olivastefania clinicalapplicationsandfuturedirectionsofminimalresidualdiseasetestinginmultiplemyeloma AT dagostinomattia clinicalapplicationsandfuturedirectionsofminimalresidualdiseasetestinginmultiplemyeloma AT boccadoromario clinicalapplicationsandfuturedirectionsofminimalresidualdiseasetestinginmultiplemyeloma AT laroccaalessandra clinicalapplicationsandfuturedirectionsofminimalresidualdiseasetestinginmultiplemyeloma |